NCT06857175 2026-04-20
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Eli Lilly and Company
National Cancer Institute (NCI)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
UroGen Pharma Ltd.
UNICANCER
Mabwell (Shanghai) Bioscience Co., Ltd.
RemeGen Co., Ltd.